David S. Ettinger
A5019357584- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Cancer therapeutics and mechanisms
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Immunotherapy and Immune Responses
- Nausea and vomiting management
- Hepatocellular Carcinoma Treatment and Prognosis
- Peptidase Inhibition and Analysis
- Sarcoma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- RNA modifications and cancer
- Anesthesia and Pain Management
- Ferroptosis and cancer prognosis
- Neuroblastoma Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Myasthenia Gravis and Thymoma
- Radiopharmaceutical Chemistry and Applications
Johns Hopkins University
2015-2024
University of Baltimore
1979-2024
Sidney Kimmel Comprehensive Cancer Center
2015-2024
Johns Hopkins Medicine
1994-2023
Sidney Kimmel Cancer Center
2011-2023
Brunswick (United States)
2020-2023
Society of Surgical Oncology
2020-2023
City of Hope
2014-2023
Clarke University
2022-2023
Box (United States)
2020-2023
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies metastatic NSCLC, because therapeutic recommendations are rapidly changing disease. For example, new were added atezolizumab, ceritinib, osimertinib, pembrolizumab 2017 updates.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management patients with NSCLC, including diagnosis, primary treatment, surveillance relapse, and subsequent treatment. Patients metastatic lung cancer who are eligible targeted therapies or immunotherapies now surviving longer. This selection from the NSCLC focuses on actionable mutations.
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management NSCLC. These Insights focus on recent updates in immunotherapy. For the 2020 update, systemic therapy regimens have been categorized using a new preference stratification system; certain are now recommended as "preferred interventions," whereas others either "other interventions" or "useful under circumstances."
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management NSCLC. These Insights focus on recent updates to the regarding targeted therapies, immunotherapies, and their respective biomarkers.
The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment recommendations for gastrointestinal stromal tumors (GISTs). standard of practice rapidly changed after the introduction effective molecularly targeted therapy (such as imatinib and sunitinib) GIST. Because these changes, organized multidisciplinary panel composed experts in fields medical oncology, molecular diagnostics, pathology, radiation surgery to discuss optimal approach care patients with GIST at all stages...
These NCCN Guidelines Insights focus on recent updates to the 2015 for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it important test tumor tissue from determine whether they alterations that make them candidates therapies. describe different testing methods currently available determining 2 most commonly actionable alterations, notably anaplastic lymphoma kinase (ALK) gene...
Untreated and minimally pretreated solid tumor patients received alternating sequences of taxol cisplatin. Sequential dose escalation each agent using doses 110 or 135 mg/m2 cisplatin 50 75 resulted in four dosage permutations that induced grades 3 4 neutropenia 72% to 84% 50% 53% courses, respectively. Neutropenia was brief, hospitalization for fever required 13% 24% courses. However, further 170 200 grade 79% 82% At the highest taxol-cisplatin level (200 mg/m2), mean neutrophil count nadir...
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management NSCLC. These Insights focus on recent updates to the targeted therapy and immunotherapy sections in Guidelines. For 2018 update, a new section biomarkers was added.
These NCCN Guidelines Insights focus on the diagnostic evaluation of suspected lung cancer. This topic was subject a major update in 2013 Clinical Practice Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer. The updates and discuss new greater detail.
Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology SCLC focus on extensive-stage because it occurs more frequently than limited-stage disease. is highly sensitive to initial therapy; however, patients eventually die recurrent In with disease, chemotherapy alone can palliate symptoms and prolong survival patients; long-term rare. Most cases attributable cigarette smoking; therefore,...
These NCCN Guidelines Insights focus on recent updates in the 2016 for Non–Small Cell Lung Cancer (NSCLC; Versions 1–4). will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, patients with metastatic NSCLC. For update, panel recommends immune checkpoint inhibitors preferred agents (in absence of contraindications) second-line beyond (subsequent) therapy NSCLC (both squamous nonsquamous histologies). Nivolumab pembrolizumab are based improved overall survival rates,...
PURPOSE A phase I and pharmacologic study was undertaken to determine the maximum-tolerated dose (MTD), describe principal toxicities, characterize behavior of topotecan, which is a semisynthetic analog camptothecin with broad preclinical antitumor activity first topoisomerase I-targeting agent enter clinical development in United States since studies sodium over 2 decades ago. PATIENTS AND METHODS Thirty-minute infusions topotecan were administered daily for 5 consecutive days every 3 weeks...
The spectrum of individual immune-related adverse events (irAEs) from anti-programmed cell death 1 (PD-1) and programmed ligand (PD-L1) immune checkpoint inhibitors (ICIs) has been reported widely, their development is associated with improved patient survival across tumor types. impact on for patients non-small lung cancer (NSCLC) who develop multisystem irAEs ICIs, not described.To characterize irAEs, association survival, risk factors irAE development.This retrospective cohort study...
Most patients with non–small cell lung cancer (NSCLC) are diagnosed advanced cancer. These guidelines only include information about stage IV NSCLC. Patients widespread metastatic disease (stage IV) candidates for systemic therapy, clinical trials, and/or palliative treatment. The goal is to identify before initiating aggressive treatment, thus sparing these from unnecessary futile If discovered during surgery, then extensive surgery often aborted. Decisions treatment should be based on...
Between October 1981 and June 1983, the Eastern Cooperative Oncology Group (ECOG) conducted a prospectively randomized trial (EST 1581) of four most active chemotherapy regimens for metastatic non-small-cell lung cancer (NSCLC). Four hundred eighty-six good performance status patients (PS 0 or 1; 81%) were to receive cyclophosphamide, doxorubicin, methotrexate, procarbazine (CAMP); mitomycin, vinblastine, cisplatin (MVP); etoposide (VP-P); vindesine (VDA-P). All administered in doses...
Between December 1979 and June 1983 the Eastern Cooperative Oncology Group (ECOG) treated 893 good-performance status patients with metastatic non-small-cell lung cancer (NSCLC) on one of seven phase III combination chemotherapies. The overall median survival was 23.5 weeks no significant differences between treatments. One hundred sixty-eight (19%) survived greater than 1 year 36 (4%) for 2 years. etoposide-platinum had highest proportion 1-year survivors (25%)....
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations management of disease in patients with NSCLC. These Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy options eligible resectable
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance relapse, and subsequent treatment. panel has updated list recommended targeted therapies based on recent FDA approvals clinical data. This selection from NSCLC focuses advanced or metastatic actionable molecular biomarkers.
2][3][4] In 2011, it is estimated that 156,900 deaths (85,600 in men, 71,300 women) from lung cancer will occur the United States. 4Five-year survival rates for are only approximately 15.6%, partly because most patients have advanced-stage at initial diagnosis (http:// seer.cancer.gov/statfacts/html/lungb.html). 5hese facts, combined with success of screening improving outcomes cervical, colon, and breast cancers,
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis address all aspects of management chemotherapy-induced nausea and vomiting. These Insights focus on recent updates to the Antiemesis, specifically those regarding carboplatin, granisetron, olanzapine.